Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
clinical_inquiry_hub@lilly.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Back

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Recruiting

Open to: ALL

Age: 18.0 - N/A

Truro Salford Stevenage Preston Bristol Rochdale Glasgow Edinburgh Nuneaton

Medical Conditions

Diabetes Mellitus
Diabetes Mellitus, Type 2

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2024 Sep 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Administered SC

Intervention Arm Group : Retatrutide Dose 1;Retatrutide Dose 2;Retatrutide Dose 3;

Intervention Type : DRUG
Intervention Description : Administered SC

Intervention Arm Group : Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • The Royal Cornwall Hospital
    Truro
    England
    TR1 3LJ
  • Salford Royal Hospital
    Salford
    Manchester
    M6 8HD
  • Lister Hospital
    Stevenage
    Hertfordshire
    SG1 4AB
  • Panthera Biopartners - Preston
    Preston
    England
    PR2 9QB
  • Southmead Hospital
    Bristol
    Bristol, City Of
    BS10 5NB
  • Panthera Biopartners - Manchester
    Rochdale
    Manchester
    OL11 4AU
  • Panthera Biopartners - Glasgow
    Glasgow
    Scotland
    G51 4LB
  • Edinburgh Royal Infirmary
    Edinburgh
    Midlothian
    EH16 4SA
  • George Eliot Hospital
    Nuneaton
    Warwickshire
    CV10 7DJ

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
clinical_inquiry_hub@lilly.com



The study is sponsored by Eli Lilly and Company




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06297603
Last updated 17 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top